Can-Fite Biopharma Ltd Sponsore (CANF) 3.56 $CANF
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
Can-Fite CEO to Deliver Scientific Presentation and Serve on Expert Panel at Purines 2014 in Bonn, Germany on July 23-27, 2014
PR Newswire - Mon Jul 21, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO and Chief Science Officer, Dr. Pnina Fishman, will participate in Purines 2014. The international conference on nucleotides, nucleosides and nucleobases, is to be held in Bonn, Germany, from July 23-27, 2014. Purines 2014 will bring together the leading international scientists in the field. At this year's conference aspects of the molecular and cellular biology of purinergic signaling will be covered as well as its role in the physiology and pathology of various organ systems and the development of novel strategies for drug development and therapy.
Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient
PR Newswire - Thu Jul 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.
Can-Fite to Exhibit at Bio International Convention in San Diego on June 23 - 26, 2014
PR Newswire - Thu Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company will exhibit at the Bio International Convention in San Diego on June 23rd through 26th, 2014 at the Israel Office of the Chief Scientist's booth #611. The Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman will conduct one-on-one meetings with potential partners, as well as present findings from Can-Fite's clinical programs to scientists and medical doctors attending the convention.
Can-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015
PR Newswire - Tue Jun 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has finalized enrollment in its Phase II/III trial of CF101 for the treatment of psoriasis with over 300 patients through 17 clinical centers in the U.S., Israel and Europe. Top line results from the trial are expected in the first quarter of 2015.
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
Can-Fite to Participate in Newport Coast Securities Conference in New York & ROTH Conference in London
PR Newswire - Tue Jun 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Chief Financial Officer, Motti Farbstein will participate in two upcoming financial conferences during the month of June. On Friday June 13, 2014 at 9:00am Mr. Farbstein will present at the Newport Coast Securities 2014 National Sales & Equity Conference in New York City. On Tuesday June 24, 2014, Mr. Farbstein will participate in small group presentations and one-on-one meetings at ROTH Capital Partners' ROTH Healthcare Corporate Access Day in London.
Can-Fite Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans
PR Newswire - Mon Jun 09, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic plans:
Can-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol
PR Newswire - Mon Jun 02, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. The FDA has granted Can-Fite Orphan Drug designation for CF102 in this indication.
Can-Fite Announces 2014 Annual General Meeting
PR Newswire - Fri May 30, 3:32PM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that its 2014 Annual General Meeting of Shareholders will be held on Monday, July 7, 2014 at 10.00 a.m. (Israel time) at the offices of the Company, 10 Bareket Street, Petach Tikva, Israel. The record date for shareholders entitled to vote at the meeting is close of business on June 2, 2014.
Can-Fite Reports First Quarter 2014 Results
PR Newswire - Thu May 29, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the first quarter ended March 31, 2014.
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Can-Fite Files 2013 Annual Report on Form 20-F
PR Newswire - Mon Mar 31, 1:28PM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-Fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
Can-Fite to Present at the 9th International Congress of Autoimmunity
PR Newswire - Tue Mar 25, 6:00AM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.
Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
PR Newswire - Mon Mar 17, 6:00AM CDT
Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.
Can-Fite BioPharma announces USD5m from private placement
M2 - Tue Mar 11, 7:14AM CDT
US-based biotechnology company Can-Fite BioPharma (Tel Aviv:CFBI.TA) (NYSE MKT:CANF) said on Monday that it has closed a USD5m private placement with healthcare institutional investors.
Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.
Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
Can-Fite CEO to Deliver Scientific Presentation and Serve on Expert Panel at Purines 2014 in Bonn, Germany on July 23-27, 2014
PR Newswire - Mon Jul 21, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company's CEO and Chief Science Officer, Dr. Pnina Fishman, will participate in Purines 2014. The international conference on nucleotides, nucleosides and nucleobases, is to be held in Bonn, Germany, from July 23-27, 2014. Purines 2014 will bring together the leading international scientists in the field. At this year's conference aspects of the molecular and cellular biology of purinergic signaling will be covered as well as its role in the physiology and pathology of various organ systems and the development of novel strategies for drug development and therapy.
Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient
PR Newswire - Thu Jul 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.
Can-Fite to Exhibit at Bio International Convention in San Diego on June 23 - 26, 2014
PR Newswire - Thu Jun 19, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today the Company will exhibit at the Bio International Convention in San Diego on June 23rd through 26th, 2014 at the Israel Office of the Chief Scientist's booth #611. The Company's CEO, Dr. Pnina Fishman and its Director of Business Development, Dr. Sari Fishman will conduct one-on-one meetings with potential partners, as well as present findings from Can-Fite's clinical programs to scientists and medical doctors attending the convention.
Can-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015
PR Newswire - Tue Jun 17, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has finalized enrollment in its Phase II/III trial of CF101 for the treatment of psoriasis with over 300 patients through 17 clinical centers in the U.S., Israel and Europe. Top line results from the trial are expected in the first quarter of 2015.
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
Can-Fite to Participate in Newport Coast Securities Conference in New York & ROTH Conference in London
PR Newswire - Tue Jun 10, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Chief Financial Officer, Motti Farbstein will participate in two upcoming financial conferences during the month of June. On Friday June 13, 2014 at 9:00am Mr. Farbstein will present at the Newport Coast Securities 2014 National Sales & Equity Conference in New York City. On Tuesday June 24, 2014, Mr. Farbstein will participate in small group presentations and one-on-one meetings at ROTH Capital Partners' ROTH Healthcare Corporate Access Day in London.
Can-Fite Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans
PR Newswire - Mon Jun 09, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary, OphthaliX, Inc., has issued an update on its clinical developments and strategic plans:
Can-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol
PR Newswire - Mon Jun 02, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer. The FDA has granted Can-Fite Orphan Drug designation for CF102 in this indication.
Can-Fite Announces 2014 Annual General Meeting
PR Newswire - Fri May 30, 3:32PM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that its 2014 Annual General Meeting of Shareholders will be held on Monday, July 7, 2014 at 10.00 a.m. (Israel time) at the offices of the Company, 10 Bareket Street, Petach Tikva, Israel. The record date for shareholders entitled to vote at the meeting is close of business on June 2, 2014.
Can-Fite Reports First Quarter 2014 Results
PR Newswire - Thu May 29, 6:00AM CDT
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the first quarter ended March 31, 2014.
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
Can-Fite Files 2013 Annual Report on Form 20-F
PR Newswire - Mon Mar 31, 1:28PM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company's website at www.canfite.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company's complete audited financial statements, free of charge. Requests can be made by contacting Can-Fite Investor Relations at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778, Israel or by phone at +972-3-9241114.
Can-Fite to Present at the 9th International Congress of Autoimmunity
PR Newswire - Tue Mar 25, 6:00AM CDT
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 9th International Congress of Autoimmunity. The conference will be held on March 26-30, 2014 at Nice Acropolis Convention Center in Nice, France.
Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
PR Newswire - Mon Mar 17, 6:00AM CDT
Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel.
Can-Fite BioPharma announces USD5m from private placement
M2 - Tue Mar 11, 7:14AM CDT
US-based biotechnology company Can-Fite BioPharma (Tel Aviv:CFBI.TA) (NYSE MKT:CANF) said on Monday that it has closed a USD5m private placement with healthcare institutional investors.
Can-Fite Completes $5 Million Private Placement
PR Newswire - Mon Mar 10, 11:44AM CDT
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million.
Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
PR Newswire - Mon Mar 03, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
Can-Fite to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Thu Feb 27, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has been invited to present at the upcoming 26th Annual ROTH Conference. The conference will be held on March 9-12, 2014 at The Ritz-Carlton Laguna Niguel in Dana Point, California.
Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
PR Newswire - Tue Feb 25, 6:00AM CST
Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Japan Patent Office (JPO) has granted a Japanese patent which bears the Patent No. 5467872 and is titled "Process for the Synthesis of IB-MECA". This patent describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceuticals ingredient (API) of the CF101 drug candidate. Under its patent rights, Can-Fite will have exclusive rights for the manufacturing of CF101 in Japan till 2028.
